Winthrop University Hospital, Mineola, NY, USA.
Clin Chest Med. 2012 Jun;33(2):363-70. doi: 10.1016/j.ccm.2012.02.008. Epub 2012 Apr 6.
There are no approved pharmacologic agents to enhance mucus clearance in non-cystic fibrosis (CF) bronchiectasis. Evidence supports the use of hyperosmolar agents in CF, and studies with inhaled mannitol and hypertonic saline are ongoing in bronchiectasis. N-acetylcysteine may act more as an antioxidant than a mucolytic in other lung diseases. Dornase α is beneficial to patients with CF, but is not useful in patients with non-CF bronchiectasis. Mucokinetic agents such as β-agonists have the potential to improve mucociliary clearance in normals and many disease states, but have not been adequately studied in patients with bronchiectasis.
目前尚无批准的药物可用于增强非囊性纤维化(CF)支气管扩张症患者的黏液清除能力。有证据支持在 CF 中使用高渗剂,目前正在进行吸入甘露醇和高渗盐水治疗支气管扩张症的研究。乙酰半胱氨酸在其他肺部疾病中的作用更像是一种抗氧化剂,而不是黏液溶解剂。多拉司琼对 CF 患者有益,但对非 CF 支气管扩张症患者无效。黏液促动剂,如β-激动剂,有可能改善正常人及许多疾病状态下的黏液纤毛清除功能,但在支气管扩张症患者中尚未得到充分研究。